Moderna Science Day Highlights Expanding Potential of mRNA Platform

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases CAMBRIDGE, MA / ACCESS Newswire / June 25, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced research and early development updates at its Science Day event. "As we execute our strategic plan to become a diversified, multi-modality biotechnology company, we are preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad mRNA pipeline and continuing to invest in research and development," said Stéphane Bancel, CEO of Moderna.

Accesswire • 2 hours ago

Moderna (MRNA) Rises As Market Takes a Dip: Key Facts

Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.

Zacks Investment Research • Jun 23, 2026

Moderna: The Comeback Is Now In Full Swing

Moderna, Inc. is transitioning from Covid-era reliance to a diversified mRNA pipeline, with a cautious buy rating and a suggested entry below $50. MRNA's mFlusiva flu vaccine highlights benefits of mRNA vaccines (speed, flexibility, manufacturing efficiency), showing superior efficacy to incumbents, with FDA approval expected soon and blockbuster potential driving 2027+ revenue ramp. Pipeline catalysts include mCombriax (Covid/Flu combo vaccine), oncology (Intismeran Autogene), and rare disease programs, supported by a solid $5.2B cash position.

Seeking Alpha • Jun 23, 2026

Should You Buy Moderna Before Aug. 5?

Investors flocked to Moderna during early pandemic days as its coronavirus vaccine delivered blockbuster revenue. Since, times have been tough for Moderna, but the company may have reached an important turning point.

The Motley Fool • Jun 22, 2026

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Modera grew revenue by 260% year over year in the first quarter. The company is trying its mRNA platform in oncology vaccines.

The Motley Fool • Jun 20, 2026

MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing

Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.

Zacks Investment Research • Jun 19, 2026

Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course ​on rejecting the drugmaker's initial application for the shot.

Reuters • Jun 18, 2026

US FDA advisers vote in favor of Moderna's flu vaccine

The U.S. Food ​and Drug Administration's advisers on ‌Thursday backed approval of ​Moderna's flu ​vaccine in adults aged ⁠50 ​and older, saying ​its benefits outweigh the risks.

Reuters • Jun 18, 2026

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of mRNA-1010, Moderna's investigational seasonal influenza vaccine, outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and voted 9-0 that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 65 years of age and older. "We appreciate the thoughtful review by the members of VRBPAC and their recognition of the clinical evidence supporting mRNA-1010," said Stéphane Bancel, Chief Executive Officer of Moderna.

Accesswire • Jun 18, 2026

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.

The Motley Fool • Jun 18, 2026